Bruno Reigner

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

Johannes Sch�ller, Jim Cassidy, Étienne Dumont et al. · Cancer Chemotherapy and Pharmacology · 2000 · 666 citations

Oncology, Chemoprevention Strategy, Gastrointestinal Oncology +10

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.

Melanie Mackean, André Planting, Chris Twelves et al. · Journal of Clinical Oncology · 1998 · 266 citations

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.

Daniel R. Budman, Neal J. Meropol, Bruno Reigner et al. · Journal of Clinical Oncology · 1998 · 257 citations

Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Chronic Kidney Disease

Iain C. Macdougall, Richard A. Robson, Sylvie Opatrná et al. · Clinical Journal of the American Society of Nephrology · 2006 · 188 citations

Hemodialysis, Urology, Renal Function +14

Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.

Bruno Reigner, Jaco J. Verweij, Luc Dirix et al. · PubMed · 1998 · 161 citations

Nutrition, Chemoprevention Strategy, Food Intake +17